Diabetes Care 38:13391346 Smits MM, Tonneijck L, Muskiet MH et al (2016) Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
The initial dose, often 2.5mg once weekly, is primarily designed to help your body gradually adjust to the medication, minimizing potential side effects, rather than immediately triggering dramatic changes
Understanding your individual risk profile and treatment options can help optimize outcomes
GLP-1 helps to promote the feeling of being full and delays the emptying of the stomach
Tamoxifen resistance features elevated IL-6/STAT3 and MAPK signaling
Part of being human involves injury and repair: joint damage, muscle strains, surgery, arthritis, and chronic inflammation